Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age
Young G, Pipe S, Hermans C, Carcao M, Castaman G, Davis J, Ducore J, Dunn A, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha I, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska K, Martinez L, Wang M, Windyga J, Alexander W, Al-Sabbagh A, Bonzo D, Macie C, Mitchell I, Wilkinson T, Shapiro A. Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age. Blood 2021, 138: 3195. DOI: 10.1182/blood-2021-147434.Peer-Reviewed Original ResearchInitial dosing regimensEntity's Board of DirectorsEptacog betaBleeding episodesPhase 3 trialCSL BehringPediatric age subgroupsConfidence intervalsTreatment successHemophilia AYears subgroupIncreasing subject ageAge subgroupsSubject ageBeta infusionAdvisory CommitteeResearch fundingOregon Health & Science UniversitySuccess proportionTreatment of bleeding episodesControl of bleeding episodesModerate bleeding episodesTreat bleeding episodesNational Hemophilia FoundationOpen-label trial
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply